Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 12/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 10/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305067 | 0.78 | JAK2 (0.44) | JAK2JAK1JAK3PTK2PDCD1 | |
| SCHEMBL2144634 | 0.74 | JAK2 (0.44) | JAK2JAK1JAK3PTK2PDCD1 | |
| SCHEMBL2145314 | 0.72 | JAK1 (0.46) | JAK2JAK1 | |
| SCHEMBL2144092 | 0.71 | JAK2 (0.42) | JAK2JAK1JAK3PTK2PDCD1 | |
| SCHEMBL2144548 | 0.71 | JAK2 (0.42) | JAK2JAK1JAK3PTK2PDCD1 | |
| SCHEMBL2144840 | 0.71 | JAK2 (0.46) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3304606 | 0.71 | JAK2 (0.42) | JAK2JAK1JAK3PTK2PDCD1 | |
| SCHEMBL2144266 | 0.70 | JAK2 (0.42) | JAK2JAK1JAK3PTK2EGFR | |
| SCHEMBL3302056 | 0.69 | JAK2 (0.42) | JAK2JAK1JAK3PTK2PDCD1 | |
| SCHEMBL2144000 | 0.69 | JAK2 (0.41) | JAK2JAK1JAK3PTK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | L3MBTL1 2124/4885JAK2 26/4885JAK1 69/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | L3MBTL1 2124/4885JAK2 26/4885JAK1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.